Log in

Relevant bibliographies by topics / Radiation therapy outcome / Journal articles

Journal articles on the topic 'Radiation therapy outcome'

To see the other types of publications on this topic, follow the link: Radiation therapy outcome.

Author: Grafiati

Published: 10 December 2022

Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Radiation therapy outcome.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Habrand, J. L., M. Austin-Seymour, S. Birnbaum, S. Wray, R. Carroll, J. Munzenrider, L. Verhey, M. Urie, and M. Goitein. "Neurovisual outcome following proton radiation therapy." International Journal of Radiation Oncology*Biology*Physics 13 (October 1987): 141. http://dx.doi.org/10.1016/0360-3016(87)91119-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Habrand, J. L., M. Austin-Seymour, S. Birnbaum, S. Wray, R. Carroll, J. Munzenrider, L. Verhey, M. Urie, and M. Goitein. "Neurovisual outcome following proton radiation therapy." International Journal of Radiation Oncology*Biology*Physics 16, no. 6 (June 1989): 1601–6. http://dx.doi.org/10.1016/0360-3016(89)90969-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Sianos, G. "Long term outcome after intracoronary radiation therapy." Heart 91, no. 7 (July 1, 2005): 942–47. http://dx.doi.org/10.1136/hrt.2004.038026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Sharp, J. G. "104Cytokines and the outcome of radiation therapy." Radiotherapy and Oncology 40 (January 1996): S29. http://dx.doi.org/10.1016/s0167-8140(96)80111-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Guney, Y., A. Hiçsönmez, MN Andrieu, and C. Kurtman. "Outcome of Aggressive Fibromatosis Treated with Radiation Therapy." Scottish Medical Journal 52, no. 4 (November 2007): 11–14. http://dx.doi.org/10.1258/rsmsmj.52.4.11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ballo, Matthew T., Gunar K. Zagars, Alan Pollack, Peter W. T. Pisters, and Raphael A. Pollock. "Desmoid Tumor: Prognostic Factors and Outcome After Surgery, Radiation Therapy, or Combined Surgery and Radiation Therapy." Journal of Clinical Oncology 17, no. 1 (January 1999): 158. http://dx.doi.org/10.1200/jco.1999.17.1.158.

Full text

Abstract:

PURPOSE: To evaluate the therapeutic value of resection and the potential benefits of and indications for adjuvant and definitive radiation therapy for desmoid tumors. MATERIALS AND METHODS: We performed a retrospective review of 189 consecutive cases of desmoid tumor treated with surgical resection, resection and radiation therapy, or radiation therapy alone. Treatment was surgery alone in 122 cases, surgery and radiation therapy in 46, and radiation therapy alone in 21. Median follow-up was 9.4 years. RESULTS: Overall, 5- and 10-year actuarial relapse rates were 30% and 33%, respectively. Uncorrected survival rates were 96%, 92%, and 87% at 5, 10, and 15 years, respectively. For the patients treated with surgery, the actuarial relapse rates were 34% and 38% at 5 and 10 years, respectively. Among 78 patients with negative margins, the 10-year recurrence rate was 27%, whereas 40 margin-positive patients had a 10-year relapse rate of 54% (P = .003). Tumors located in an extremity also had a poorer prognosis than did those in the trunk. For patients treated with radiation therapy for gross disease, the 10-year actuarial relapse rate was 24%. For patients treated with combined resection and radiation therapy, the 10-year actuarial relapse rate was 25%. The addition of radiation therapy offset the adverse impact of positive margins seen in the surgical group. CONCLUSION: Wide local excision with negative pathologic margins is the treatment of choice for most desmoid tumors. Function-sparing resection is appropriate because adjuvant radiation therapy can offset the adverse impact of positive margins. Unresectable disease should be treated with definitive radiation therapy.

APA, Harvard, Vancouver, ISO, and other styles

7

Smith, Jonathan C., Jonas T. Johnson, and Eugene N. Myers. "Management and outcome of early glottic carcinoma." Otolaryngology–Head and Neck Surgery 126, no. 4 (April 2002): 356–64. http://dx.doi.org/10.1067/mhn.2002.123858.

Full text

Abstract:

OBJECTIVE AND STUDY DESIGN: We designed a retrospective study to analyze treatment methods and outcomes for patients with lesions ranging from carcinoma in situ to invasive T1 glottic squamous cell carcinoma. Patients with nonsquamous cell carcinoma, verrucous variant of squamous cell carcinoma, anterior commissure involvement, and T2 lesions were excluded. SETTING: University of Pittsburgh School of Medicine, a tertiary referral center. RESULTS: Fifty-four patients met the inclusion criteria. Mean follow-up was 49 months (range 24 to 96 months). Forty-eight of 54 (89%) were treated with endoscopic excision. Forty of these 48 patients (83%) were successfully treated with endoscopic excision(s) as the only treatment modality. Four patients had persistence of disease despite multiple endoscopic excisions. Two of these patients underwent hemilaryngectomy, 1 received radiation treatment, and 1 received radiation therapy followed by a hemilaryngectomy. Four patients had recurrence of disease. Two patients with recurrence required radiation therapy and 2 patients required a total laryngectomy. With the selective application of multiple endoscopic excisions, radiation therapy, and more invasive operation, 100% of patients are without evidence of disease with a laryngeal preservation rate of 96%. CONCLUSIONS: This study supports the use of endoscopic excisional biopsy as the primary treatment modality for lesions ranging from carcinoma in situ to invasive T1 glottic carcinoma. This study also highlights the importance of close clinical follow-up and the potential need for further treatment. By reserving open operation and radiation therapy to selective cases, we successfully treated all patients while limiting the disadvantages of radiation therapy and more invasive operation to the minority of patients.

APA, Harvard, Vancouver, ISO, and other styles

8

Fox‐Alvarez, Stacey, Keijiro Shiomitsu, Amandine T. Lejeune, Anna Szivek, and Lyndsay Kubicek. "Outcome of intensity‐modulated radiation therapy‐based stereotactic radiation therapy for treatment of canine nasal carcinomas." Veterinary Radiology & Ultrasound 61, no. 3 (March 18, 2020): 370–78. http://dx.doi.org/10.1111/vru.12854.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

HOYE, A. "P2223 Long-term outcome after intracoronary beta radiation therapy." European Heart Journal 24, no. 5 (March 2003): 422. http://dx.doi.org/10.1016/s0195-668x(03)95217-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Myerson, R. J., J. M. Michalski, M. L. King, E. Birnbaum, J. Fleshman, R. Fry, I. Kodner, D. Lacey, and M. Lockett. "Adjuvant radiation therapy for rectal carcinoma: Predictors of outcome." International Journal of Radiation Oncology*Biology*Physics 27 (1993): 276–77. http://dx.doi.org/10.1016/0360-3016(93)90872-s.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Myerson, Robert J., Jeff M. Michalski, Maurice L. King, Elisa Birnbaum, James Fleshman, Robert Fry, Ira Kodner, David Lacey, and Mary Ann Lockett. "Adjuvant radiation therapy for rectal carcinoma: Predictors of outcome." International Journal of Radiation Oncology*Biology*Physics 32, no. 1 (April 1995): 41–50. http://dx.doi.org/10.1016/0360-3016(94)00493-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Nguyen, N. T., Y. Wang, L. L. Lyon, and J. L. Villano. "Impact of Radiation Therapy on Clinical Outcome of Meningiomas." International Journal of Radiation Oncology*Biology*Physics 87, no. 2 (October 2013): S262—S263. http://dx.doi.org/10.1016/j.ijrobp.2013.06.684.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Koontz, B. F., N. S. Kalman, L. L. Bañez, K. P. Livengood, M. S. Anscher, J. W. Moul, and W. R. Lee. "Image Guidance Affects Biochemical Outcome for Postprostatectomy Radiation Therapy." International Journal of Radiation Oncology*Biology*Physics 87, no. 2 (October 2013): S362—S363. http://dx.doi.org/10.1016/j.ijrobp.2013.06.953.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Abu-Hijlih, R. A., Y. Ismael, H. Ghatasheh, A. Fawzi, A. Alsharbaji, M. Elyan, B. Al-Haj, and A. Almousa. "Clinical Outcome after Fractionated Radiation Therapy for Pituitary Adenoma." International Journal of Radiation Oncology*Biology*Physics 93, no. 3 (November 2015): E62—E63. http://dx.doi.org/10.1016/j.ijrobp.2015.07.703.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Rieken, Stefan, Angela Mohr, Daniel Habermehl, Thomas Welzel, Katja Lindel, Olaf Witt, Andreas E. Kulozik, Wolfgang Wick, Jürgen Debus, and Stephanie E. Combs. "Outcome and Prognostic Factors of Radiation Therapy for Medulloblastoma." International Journal of Radiation Oncology*Biology*Physics 81, no. 3 (November 2011): e7-e13. http://dx.doi.org/10.1016/j.ijrobp.2010.12.042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Huang, Chih-Jen, K. S. Clifford Chao, Jason Tsai, Joseph R. Simpson, Bruce Haughey, Gershon J. Spector, and Donald G. Sessions. "Cancer of retromolar trigone: Long-term radiation therapy outcome." Head & Neck 23, no. 9 (2001): 758–63. http://dx.doi.org/10.1002/hed.1108.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Leibel, Steven A., and Glenn E. Sheline. "Radiation therapy for neoplasms of the brain." Journal of Neurosurgery 66, no. 1 (January 1987): 1–22. http://dx.doi.org/10.3171/jns.1987.66.1.0001.

Full text

Abstract:

✓ The effectiveness and complications of radiation therapy for brain neoplasms are reviewed. While the available data suggest a favorable influence and outcome, randomized studies are needed to further optimize radiation therapy techniques and to integrate new therapeutic modalities.

APA, Harvard, Vancouver, ISO, and other styles

18

IM, CHAN-MUK, ICK-JOON CHO, HYUNG-JOO YU, BORA HAN, HYUNG-HOON OH, YOON-JIN SEO, KI-HYUN KIM, et al. "Clinical Outcome and Risk Factors of Chronic Radiation Proctitis Following Pelvic Radiation Therapy." Anticancer Research 42, no. 12 (December 2022): 5951–59. http://dx.doi.org/10.21873/anticanres.16105.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Baranyai, Zsolt, Dániel Sinkó, Valéria Jósa, Attila Zaránd, and Dániel Teknős. "Therapy of radiation enteritis – current challenges." Orvosi Hetilap 152, no. 28 (July 2011): 1120–24. http://dx.doi.org/10.1556/oh.2011.29141.

Full text

Abstract:

Radiation enteritis is one of the most feared complications after abdominal and pelvic radiation therapy. The incidence varies from 0.5 to 5%. It is not rare that the slowly progressing condition will be fatal. During a period of 13 years 24 patients were operated due to the complication of radiation enteritis. Despite different types of surgery repeated operation was required in 25% of cases and finally 4 patients died. Analyzing these cases predisposing factors and different therapeutic options of this condition are discussed. Treatment options of radiation induced enteritis are limited; however, targeted therapy significantly improves the outcome. Cooperation between oncologist, gastroenterologist and surgeon is required to establish adequate therapeutic plan. Orv. Hetil., 2011, 152, 1120–1124.

APA, Harvard, Vancouver, ISO, and other styles

20

Wisdom, Amy J., Cierra S. Hong, Alexander J. Lin, Yu Xiang, Daniel E. Cooper, Jin Zhang, Eric S. Xu, et al. "Neutrophils promote tumor resistance to radiation therapy." Proceedings of the National Academy of Sciences 116, no. 37 (August 28, 2019): 18584–89. http://dx.doi.org/10.1073/pnas.1901562116.

Full text

Abstract:

Nearly two-thirds of cancer patients are treated with radiation therapy (RT), often with the intent to achieve complete and permanent tumor regression (local control). RT is the primary treatment modality used to achieve local control for many malignancies, including locally advanced cervical cancer, head and neck cancer, and lung cancer. The addition of concurrent platinum-based radiosensitizing chemotherapy improves local control and patient survival. Enhanced outcomes with concurrent chemoradiotherapy may result from increased direct killing of tumor cells and effects on nontumor cell populations. Many patients treated with concurrent chemoradiotherapy exhibit a decline in neutrophil count, but the effects of neutrophils on radiation therapy are controversial. To investigate the clinical significance of neutrophils in the response to RT, we examined patient outcomes and circulating neutrophil counts in cervical cancer patients treated with definitive chemoradiation. Although pretreatment neutrophil count did not correlate with outcome, lower absolute neutrophil count after starting concurrent chemoradiotherapy was associated with higher rates of local control, metastasis-free survival, and overall survival. To define the role of neutrophils in tumor response to RT, we used genetic and pharmacological approaches to deplete neutrophils in an autochthonous mouse model of soft tissue sarcoma. Neutrophil depletion prior to image-guided focal irradiation improved tumor response to RT. Our results indicate that neutrophils promote resistance to radiation therapy. The efficacy of chemoradiotherapy may depend on the impact of treatment on peripheral neutrophil count, which has the potential to serve as an inexpensive and widely available biomarker.

APA, Harvard, Vancouver, ISO, and other styles

21

D'Amico, A. V., R. Whittington, S. B. Malkowicz, D. Schultz, K. Blank, G. A. Broderick, J. E. Tomaszewski, et al. "Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer." Journal of Urology 161, no. 4 (April 1999): 1393. http://dx.doi.org/10.1016/s0022-5347(01)61700-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

D'Amico, Anthony V. "Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer." JAMA 280, no. 11 (September 16, 1998): 969. http://dx.doi.org/10.1001/jama.280.11.969.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

MAGALHÃES, TOMÁS RODRIGUES, JÉRÔME BENOÎT, SLAVOMÍRA NÉČOVÁ, SUSAN NORTH, and FELISBINA LUÍSA QUEIROGA. "Outcome After Radiation Therapy in Canine Intracranial Meningiomas or Gliomas." In Vivo 35, no. 2 (2021): 1117–23. http://dx.doi.org/10.21873/invivo.12357.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Strom, Tobin, Javier F. Torres-Roca, Akash Parekh, Arash O. Naghavi, Jimmy J. Caudell, Daniel E. Oliver, Jane L. Messina, et al. "Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma." Journal of the National Comprehensive Cancer Network 15, no. 4 (April 2017): 473–82. http://dx.doi.org/10.6004/jnccn.2017.0047.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Koide, Yutaro, Takeshi Kodaira, Hiroyuki Tachibana, Natsuo Tomita, Chiyoko Makita, Makoto Itoh, Tetsuya Abe, et al. "Clinical outcome of definitive radiation therapy for superficial esophageal cancer." Japanese Journal of Clinical Oncology 47, no. 5 (February 23, 2017): 393–400. http://dx.doi.org/10.1093/jjco/hyx021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Gage, Irene, Abram Recht, Rebecca Gelman, Asa J. Nixon, Barbara Silver, Bruce A. Bornstein, and Jay R. Harris. "Long-term outcome following breast-conserving surgery and radiation therapy." International Journal of Radiation Oncology*Biology*Physics 33, no. 2 (September 1995): 245–51. http://dx.doi.org/10.1016/0360-3016(95)02001-r.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Koide, Y., K. Kimura, M. Yoshida, M. Ito, C. Makita, N. Tomita, H. Tachibana, et al. "Clinical Outcome of Definitive Radiation Therapy for Superficial Esophageal Cancer." International Journal of Radiation Oncology*Biology*Physics 96, no. 2 (October 2016): E139—E140. http://dx.doi.org/10.1016/j.ijrobp.2016.06.941.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Lee, L. J., R. DeMaria, K. Mirabeau-Beale, N. Horowitz, and A. Viswanathan. "Salvage Radiation Therapy for Recurrent Vulvar SCC: Presentation and Outcome." International Journal of Radiation Oncology*Biology*Physics 87, no. 2 (October 2013): S424—S425. http://dx.doi.org/10.1016/j.ijrobp.2013.06.1118.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Tatewaki, K., T. Murai, N. Yokota, S. Ohta, M. Inoue, K. Sato, and I. Koike. "Long-term Outcome of Stereotactic Radiation Therapy for Vestibular Schwannomas." International Journal of Radiation Oncology*Biology*Physics 87, no. 2 (October 2013): S261. http://dx.doi.org/10.1016/j.ijrobp.2013.06.679.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Tsang, Richard W., James D. Brierley, Tony Panzarella, Mary K. Gospodarowicz, Simon B. Sutcliffe, and W. John Simpson. "Radiation therapy for pituitary adenoma: Treatment outcome and prognostic factors." International Journal of Radiation Oncology*Biology*Physics 30, no. 3 (October 1994): 557–65. http://dx.doi.org/10.1016/0360-3016(92)90941-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Paek, Sun Ha, Jung-Ho Han, Jin Wook Kim, Chul-Kee Park, Hee-Won Jung, Sung-Hye Park, Il Han Kim, and Dong Gyu Kim. "Long-term outcome of conventional radiation therapy for central neurocytoma." Journal of Neuro-Oncology 90, no. 1 (June 20, 2008): 25–30. http://dx.doi.org/10.1007/s11060-008-9622-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Mitsuhashi, Norio, Masaya Furuta, Hideyuki Sakurai, Takeo Takahashi, Shingo Kato, Miwako Nozaki, Yoshihiro Saito, Kazushige Hayakawa, and Hideo Niibe. "Outcome of radiation therapy for patients with Kasabach-Merritt syndrome." International Journal of Radiation Oncology*Biology*Physics 39, no. 2 (September 1997): 467–73. http://dx.doi.org/10.1016/s0360-3016(97)00140-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Jain, Neelam, Kevin R. Krull, Pim Brouwers, Murali M. Chintagumpala, and Shiao Y. Woo. "Neuropsychological outcome following intensity-modulated radiation therapy for pediatric medulloblastoma." Pediatric Blood & Cancer 51, no. 2 (August 2008): 275–79. http://dx.doi.org/10.1002/pbc.21580.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Rieken, S., A. Mohr, L. Zipp, K. Lindel, J. Debus, and S. E. Combs. "Treatment Outcome and Prognostic Factors in Medulloblastomas after Radiation Therapy." International Journal of Radiation Oncology*Biology*Physics 78, no. 3 (November 2010): S283. http://dx.doi.org/10.1016/j.ijrobp.2010.07.673.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Gajjar, A., R. K. Mulhern, R. L. Heideman, R. A. Sanford, E. C. Douglass, E. H. Kovnar, J. A. Langston, J. J. Jenkins, and L. E. Kun. "Medulloblastoma in very young children: outcome of definitive craniospinal irradiation following incomplete response to chemotherapy." Journal of Clinical Oncology 12, no. 6 (June 1994): 1212–16. http://dx.doi.org/10.1200/jco.1994.12.6.1212.

Full text

Abstract:

PURPOSE To evaluate survival and neurodevelopmental outcomes following radiation therapy in infants and young children with residual or progressive medulloblastoma after primary chemotherapy. PATIENTS AND METHODS Thirteen young patients (< or = 36 months old) with medulloblastoma were treated with preirradiation multiagent chemotherapy and maximal surgical resection. Patients were scheduled to receive radiation therapy at the time of documented disease progression or upon completion of chemotherapy with residual disease. All patients underwent neurodevelopmental evaluation at the time of diagnosis, before receiving radiation therapy, and at yearly intervals posttreatment. RESULTS Two patients completed the scheduled chemotherapy with residual disease and received delayed radiation therapy. The remaining 11 patients had either local or leptomeningeal progression during chemotherapy (median time to progression, 5 months). Six patients had a complete response (CR) to radiation therapy, and three of these children are alive 48 to 104 months postdiagnosis. Of the five patients who had progressive disease (PD) during radiation therapy or residual imaging abnormalities after treatment, only one is alive (with stable enhancing leptomeningeal abnormalities) 48 months postirradiation. Two additional survivors were rendered disease-free by surgical resection before radiation therapy and are without evidence of disease at 91 and 107 months after diagnosis. Thus, six of 13 patients are alive at 48 to 107 months postdiagnosis. Neurodevelopmental scores tended to be below age norms at diagnosis; scores improved during chemotherapy, but then decreased during posttreatment follow-up evaluation. CONCLUSION Radiation therapy appears to produce long-term disease-free survival in a proportion of very young patients who have progressive or residual medulloblastoma during or after primary chemotherapy. However, neurodevelopmental deficits are frequent among long-term survivors.

APA, Harvard, Vancouver, ISO, and other styles

36

Ibrahim, Sameh R. A., Alexey Shkarubo, Ludmila Astafyeva, Gennady Chmutin, and Egor Chmutin. "ADVANCES IN THE NEUROSURGICAL AND COMBINED TREATMENT OF PATIENTS WITH ACROMEGALY." Archiv Euromedica 11, no. 4 (September 30, 2021): 104–7. http://dx.doi.org/10.35630/2199-885x/2021/11/4.25.

Full text

Abstract:

Aim. The study was carried out to identify and analyze the factors of a positive outcome of surgical and radiation treatment of acromegaly. Methods. The work was performed on clinical material and summarizes treatment results of 256 patients (90 males and 166 females). 86% of patients underwent surgical treatment, 14% of patients received radiation therapy during 2002–2018. Significance of factors of a positive outcome of treatment was carried out using the RStudio program. Results. The results of the study revealed that: 1. Significant factors (p <0.05) of a positive outcome of surgical treatment of acromegaly are somatostatin analogs (SSA) therapy before surgery, a small tumor size (microadenomas), and the absence of extrasellar tumor spread. 2. The most significant factor in achieving remission of acromegaly after non-radical adenomectomy is postoperative therapy with SSA (p <0.05). 3. Aggressive pituitary tumors invading surrounding structures, high baseline IGF-1 levels, unfavorable histological findings, macroadenomas, growth hormone levels above 10 μg/L before therapy, and extrasellar tumor spread were associated with less favorable outcomes of acromegaly radiation therapy (RT) (p <0.05). The most significant factor in achieving remission of acromegaly is SSA therapy after RT (p <0.05). Conclusion. Surgical treatment is the optimal primary treatment for acromegaly. Drug therapy with SSA is effective and the preferred treatment after non-radical surgery.

APA, Harvard, Vancouver, ISO, and other styles

37

Matsuda, Masahide, Masashi Mizumoto, Hidehiro Kohzuki, Narushi Sugii, and Eiichi Ishikawa. "RT-4 Treatment outcome of proton beam therapy for glioblastoma." Neuro-Oncology Advances 3, Supplement_6 (December 1, 2021): vi15. http://dx.doi.org/10.1093/noajnl/vdab159.055.

Full text

Abstract:

Abstract Introduction: Proton beam therapy enables high dose irradiation for tumors while reducing the dose to surrounding normal tissue due to the sharp energy peak called the Bragg peak. We retrospectively analyzed the efficacy of the high dose radiotherapeutic strategy using proton beam for glioblastoma (GBM) in our institution. Methods: Twenty-nine patients with newly diagnosed GBM who underwent high dose proton beam therapy concomitant with temozolomide were investigated. All patients received hyperfractionated concomitant radiotherapy consisting of X-ray radiotherapy (50.4Gy in 28 fractions) and proton beam therapy (46.2Gy [RBE] in 28 fractions). The survival outcome and adverse events were analyzed. Results: The median overall survival time and progression free survival time for all 29 patients were 31.0 months (95%CI, 25.9–36.1) and 11.0 months (95%CI, 7.8–14.2), respectively. No significant survival difference according to the MGMT methylation status was shown. Failure patterns after proton beam therapy included 17 cases of local recurrence, 3 cases of distant recurrence, and 5 cases of dissemination. Although there was no significant difference in time to recurrence according to the failure pattern, there was a tendency of longer survival in the local recurrence group. Regarding adverse events, radiation necrosis was observed in 8 cases (including 2 asymptomatic cases). The median time to onset of necrosis after radiation was 18.2 months (95%CI, 10.3–26.2). There were 5 cases of long survivor over 5 years out of 29 cases (17.2%). Of these, 4 cases developed radiation necrosis. Conclusions: Our results indicate that high dose proton beam therapy of 96.6Gy (RBE) prolonged survival in selected GBM patients. Particularly in long survivors, special attention and effective treatment to radiation necrosis is a remaining problem.

APA, Harvard, Vancouver, ISO, and other styles

38

Glatzer, Markus, Olgun Elicin, Sara Ramella, Ursula Nestle, and Paul Martin Putora. "Radio(chemo)therapy in locally advanced nonsmall cell lung cancer." European Respiratory Review 25, no. 139 (February 29, 2016): 65–70. http://dx.doi.org/10.1183/16000617.0053-2015.

Full text

Abstract:

Definitive radiochemotherapy is the standard treatment for many patients with locally advanced nonsmall cell lung cancer (NSCLC). Treatment outcomes have improved over the last decades. Several treatment regimens have been shown effective and safe. This review summarises the results of significant studies between 1996 and 2015 on concomitant and sequential radiochemotherapy regimens and radiation dose per fraction. Beside therapy regimens, optimised radiotherapy planning is indispensable to improve outcome and minimise radiation-induced toxicity. An insight into the rationale of radiotherapy planning for stage III NSCLC is also provided.

APA, Harvard, Vancouver, ISO, and other styles

39

Ohba, Shigeo, Masahito Kobayashi, Takashi Horiguchi, Satoshi Onozuka, Kazunari Yoshida, Takayuki Ohira, and Takeshi Kawase. "Long-term surgical outcome and biological prognostic factors in patients with skull base meningiomas." Journal of Neurosurgery 114, no. 5 (May 2011): 1278–87. http://dx.doi.org/10.3171/2010.11.jns10701.

Full text

Abstract:

Object Although gross-total resection (GTR) is a preferable treatment for skull base meningiomas, subtotal resection (STR) with or without radiation therapy can be considered as an alternative treatment for patients at considerable surgical risk. The long-term prognosis of such patients might be related to the biological activity of the tumor. This study examined predictors of progression-free survival (PFS) and sought to determine the optimal treatment strategies, focusing on the pathobiological findings of skull base meningiomas. Methods This study included 281 patients with skull base meningiomas (mean follow-up period 88.4 months). Risk factors for tumor progression were examined using a multivariate analysis. The PFS and overall survival (OS) rates were evaluated using the Kaplan-Meier method. The functional outcomes of the patients were measured using the Karnofsky Performance Scale (KPS). Results The 10-year PFS and OS rates were 66.4% and 97.4%, respectively. Overall, 83.3% of patients achieved a favorable outcome, that is, an improved or unchanged KPS score. The extent of resection, additional radiotherapy, histological grade, MIB-1 index, and p53-positive rate were significantly associated with PFS. The PFS of patients undergoing STR without radiation therapy was significantly shorter than that of either those undergoing STR with radiation therapy or GTR, while no statistical difference was observed between the latter 2 groups. Among the patients undergoing STR with pathobiological risk factors (histological grade, MIB-1 index, and p53-positive rate), the PFS of the patients who received radiation therapy was better than that of those who did not receive radiation therapy. Among the patients undergoing STR without such risk factors, the PFS was not significantly different between patients who received radiation therapy and those who did not. Conclusions For patients with skull base meningiomas, a GTR is desirable and additional radiation therapy after STR may contribute to a longer PFS. Additional radiation therapy should be recommended, especially for patients with pathobiological risk factors, but not necessarily for those without such risks.

APA, Harvard, Vancouver, ISO, and other styles

40

Matsuda, Kenichiro, Kaori Sakurada, Takamasa Kayama, and Yukihiko Sonoda. "GCT-16. LONG-TERM CLINICAL OUTCOMES OF GERM CELL TUMORS." Neuro-Oncology 22, Supplement_3 (December 1, 2020): iii331. http://dx.doi.org/10.1093/neuonc/noaa222.236.

Full text

Abstract:

Abstract BACKGROUND Intracranial germ cell tumors (GCT) are mainly arising in adolescent term and treated with chemotherapy concomitant with radiation therapy. There is accumulating evidence that the progress of treatment. Besides, long-term outcome and adverse effects are major problem in treatment. So, we must grasp the influence of these outcomes on daily and social life. Then we investigated in clinical outcome in cases of GCT treated in our institution. METHOD: We reviewed the clinical features and outcomes of 52 cases of intracranial GCT in 1975 to 2019. Ages on diagnosis are 5–35 years old (median 14 years old), consisted with 44 male cases. The pathological distributions are these: pure germinoma: 40 cases, non-germinomatous germ cell tumor (NGGCT): 10 cases (mature teratoma: 4, mixed germ cell tumors: 3, and one cases of choriocarcinoma, embryonal carcinoma, yolk sac tumor), unidentified pathology: 2 cases. Almost all cases have biopsied and treated by chemotherapy and radiation therapy. RESULTS Chemotherapy with ICE regimen (ifosphamide, cisplatin, etoposide) or CARE regimen (carboplatin, etoposide) concomitant with radiation therapy (mainly, extended local irradiation) have done in almost cases by the era. Clinical outcomes are relatively well in our cases, but 10 cases experienced recurrence. 3 cases have dead. Some cases with suprasellar involvement have need hormone replacement in long term. There are 10 cases at work. CONCLUSION Almost cases have gained better outcome and ADL. But there is slightly lower rate in work or marriage. Serial evaluation in outcome, and higher brain functions should be performed in follow up.

APA, Harvard, Vancouver, ISO, and other styles

41

Cicėnas, Saulius, Aurelija Žalienė, and Vydmantas Atkočius. "Treatment outcome of locally advanced stage IIIA/B lung cancer." Medicina 45, no. 6 (June 8, 2009): 452. http://dx.doi.org/10.3390/medicina45060059.

Full text

Abstract:

Objective. To determine survival of patients with stage IIIA/B non–small cell lung cancer considering disease stage and treatment methods. Material and methods. A total of 304 patients with non–small cell lung cancer were treated at the Department of Thoracic Surgery and Oncology, Institute of Oncology, Vilnius University, in 2000–2004. Stage IIIA (T3N1-2M0) cancer was diagnosed for 193 (63.5%) patients and stage IIIB (T4N0-1M0) cancer was diagnosed for 111 (36.5%) patients. There were 277 (91.1%) males and 27 (8.9%) females. According to morphology, there were 219 (72%) patients with squamous cell lung cancer, 80 (26.3%) with adenocarcinoma, and 5 (1.7%) patients with large cell carcinoma. Surgery was performed in 145 patients: 84 (57.9%) patients underwent lung resection (T3-4N0-1M0), 51 (35.2%) patients – thoracotomy, and 10 (6.7%) patients – other palliative thoracic procedures (mediastinotomy, pleurectomy, mediastinoscopy). Forty-eight (30.2%) patients were treated with radiation therapy with total doses of >40 Gy and 58 (36.5%) patients were treated with radiation therapy with total doses of <40 Gy. Fifty-four (33.9%) patients were treated with Gemzar and cisplatin and 19 (11.9%) patients were treated with etoposide and cisplatin.Results. Overall median and mean survival was 7.8 months (95% CI, 6.8 to 8.8) and 9.9 months (95% CI, 9.0 to 10.9), respectively. The median and mean survival of patients with stage IIIA cancer was 8.3 months and 10.4 months, respectively, and that of patients with stage IIIB cancer – 6.4 months and 9.0 months, respectively (P≤0.05). The median survival of the patients with stage IIIA cancer who received a combination of operation, chemotherapy, and radiation therapy with a total dose of >40 Gy was 14.4 months (mean, 14.7 months), and the median survival of those who received operation, chemotherapy, and radiation therapy with a total dose of ≤40 Gy was 9.7 months (mean, 14.1 months); the median survival of the patients who underwent surgery alone was 4.9 months (mean, 6.7 months) (P=0.004 and P=0.007), respectively. There was a significant difference in the median survival comparing the patients with stage IIIB cancer who underwent surgery alone and those who received a combination of radiation therapy and chemotherapy (median survival of 5.0 months [mean, 8.1 months] versus 16.8 months [mean, 17.6 months], respectively; P≤0.05). Conclusions. Disease stage had an influence on the survival of patients with non–small cell lung cancer: patients with stage IIIA (T3N0-1M0) cancer without metastases to mediastinal lymph nodes (N factor) survived longer than patients with stage IIIB (T4N1-2M0) cancer, where not only N factor had an impact but T factor as well. Better treatment outcomes, i.e. longer survival, can be achieved when a combination of three treatment types – surgery, chemotherapy, and radiation therapy – is applied to patients with stage IIIA or IIIB non–small cell lung cancer. The patients with stage IIIA disease who received surgery and radiation therapy (total dose, >40 Gy), and combinations of surgery, chemotherapy, and radiation therapy and second-line chemotherapy showed a significantly longer survival than those who received surgery alone.

APA, Harvard, Vancouver, ISO, and other styles

42

Endo, Fumitaka, Yuji Akiyama, Shigeaki Baba, Haruka Nikai, Akira Umemura, Hirokatsu Katagiri, Takeshi Iwaya, et al. "P9-7 Treatment outcome following nivolumab therapy administered after radiation therapy for esophageal cancer." Annals of Oncology 33 (July 2022): S515—S516. http://dx.doi.org/10.1016/j.annonc.2022.05.243.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Buchholz, Thomas A. "How Does Biology Affect Local Therapy Decisions?" American Society of Clinical Oncology Educational Book, no. 32 (June 2012): 56–57. http://dx.doi.org/10.14694/edbook_am.2012.32.62.

Full text

Abstract:

Overview: Breast cancer represents a biologically diverse set of diseases. Previous data suggest that the estrogen/progesterone receptor (ER/PR) status and HER2/ neu status are important determinants of prognosis and response to various systemic treatments. Recent data also suggest that these receptors correlate with outcomes of local-regional therapies. Specifically, patients with ER-positive HER2/ neu-negative disease have an excellent outcome with radiation treatments, either given as a component of breast-conservative therapy (BCT) or for those with more advanced disease, when given after mastectomy. For patients with triple-negative disease, data suggest that the proportional benefits offered from radiation in reducing local-regional recurrences may be less. This article will highlight some of these data and discuss strategies for new local-regional research avenues that are based on breast cancer biologic subtype.

APA, Harvard, Vancouver, ISO, and other styles

44

Tali, Tavseef Ahmad, Fiza Amin, Javaid Ahmad Dar, Mushtaq Ahmad Sofi, and Nazir Ahmad Dar. "Clinical Profile and Treatment Outcome of Chordoma: A Tertiary Care Experience in North India." Indonesian Journal of Cancer Chemoprevention 13, no. 2 (November 30, 2022): 137. http://dx.doi.org/10.14499/indonesianjcanchemoprev13iss2pp137-143.

Full text

Abstract:

Chordoma is a slow growing cancer of tissue found inside the spine. Chordoma can happen anywhere along the spine. It is most often found near the tailbone (called a sacral tumor) or where the spine meets the skull (called a clival tumor). Chordoma is also called notochordal sarcoma. The main objective of this study was to determine the clinical profile and treatment outcome of chordoma patients. All the patients were diagnosed using radiological imaging and biopsy. The site of origin of chordoma was the sacrum in seventeen (71%) patients, the spine in six (25%) patients, and the skull base in one (4%) patient. 21 (88%) of the twenty-four patients received primary surgery. These 21 patients then received adjuvant radiation therapy using the intensity modulated radiation therapy (IMRT) strategy, with radiation dose ranging from 70Gy to 74Gy. Three patients (12%) did not undergo surgery; two had low performance status and received only radiotherapy; the third with the disease at the base of the skull was unresectable; this patient received radiotherapy first, then imatinib. Compared to individuals who get radiation alone, the addition of adjuvant radiation therapy to surgery in chordoma patients enhances overall survival.Keywords: chordoma, radiotherapy, targeted therapy.

APA, Harvard, Vancouver, ISO, and other styles

45

Sah, Bindeshwar, Jing Wu, Adam Vanasse, Nil Kanatha Pandey, Lalit Chudal, Zhenzhen Huang, Wenzhi Song, et al. "Effects of Nanoparticle Size and Radiation Energy on Copper-Cysteamine Nanoparticles for X-ray Induced Photodynamic Therapy." Nanomaterials 10, no. 6 (June 1, 2020): 1087. http://dx.doi.org/10.3390/nano10061087.

Full text

Abstract:

The Copper-cysteamine (Cu-Cy) nanoparticle is a novel sensitizer with a potential to increase the effectiveness of radiation therapy for cancer treatment. In this work, the effect of nanoparticle size and the energy of X-rays on the effectiveness of radiation therapy are investigated. The effect of the particle size on their performance is very complicated. The nanoparticles with an average size of 300 nm have the most intense photoluminescence, the nanoparticles with the average size of 100 nm have the most reactive oxygen species production upon X-ray irradiation, while the nanoparticles with the average size of 40 nm have the best outcome in the tumor suppression in mice upon X-ray irradiation. For energy, 90 kVp radiation resulted in smaller tumor sizes than 250 kVp or 350 kVp radiation energies. Overall, knowledge of the effect of nanoparticle size and radiation energy on radiation therapy outcomes could be useful for future applications of Cu-Cy nanoparticles.

APA, Harvard, Vancouver, ISO, and other styles

46

Shihadeh, E. D., S. Ryu, J. A. Bogart, C. T. Chung, and M. Rogers. "2096 Outcome of radiation therapy alone and post-operative radiation for non-functioning pituitary adenoma." International Journal of Radiation Oncology*Biology*Physics 45, no. 3 (January 1999): 326–27. http://dx.doi.org/10.1016/s0360-3016(99)90366-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Li, Hualei, Mindi J. TenNapel, Amina Ahmed, Lilie Lin, Sudershan K. Bhatia, and Geraldine Jacobson. "Uterine Carcinosarcoma Confined to the Pelvis: A Retrospective Review and Outcome Analysis." Journal of Radiotherapy 2014 (March 11, 2014): 1–8. http://dx.doi.org/10.1155/2014/124149.

Full text

Abstract:

Objective. We compared the treatments of uterine carcinosarcoma at our institution and evaluated their impact on survival. Methods. A retrospective analysis was performed on 60 eligible patients with carcinosarcoma limited to the pelvis. Subjects were divided into four categories: surgery, surgery plus chemotherapy, surgery plus radiation therapy, and a combination of surgery, chemotherapy, and RT. The most commonly used chemotherapy was cisplatin and/or carboplatin and taxol. Radiotherapy included external beam radiation therapy (EBRT) alone or with high dose rate (HDR) brachytherapy or HDR brachytherapy alone. Survival probability data were computed using the Kaplan-Meier method. The differences between groups were compared using the log-rank test. Results. The combination of surgery and radiation therapy with or without chemotherapy is seen to improve overall survival (OS) compared to surgery alone (P=0.044 and P=0.028, resp.). Brachytherapy involving three HDR vaginal cylinder fractions shows an equally effective reduction in local recurrence compared to EBRT. Conclusion. Our study of a relatively large number of carcinosarcoma patients suggests that adjuvant radiation therapy improves OS compared to surgery alone. Brachytherapy with 3 HDR vaginal cylinder fractions is preferred because of its time-saving, better tolerance, low toxicity and equivalent OS, and local control compared to EBRT.

APA, Harvard, Vancouver, ISO, and other styles

48

Lee, Hansang, Dongryul Oh, Kyungmi Yang, Young Hyeh Ko, Yong Chan Ahn, Won Seog Kim, and Seok Jin Kim. "Radiation Therapy Outcome and Clinical Features of Duodenal-Type Follicular Lymphoma." Cancer Research and Treatment 51, no. 2 (April 15, 2019): 547–55. http://dx.doi.org/10.4143/crt.2018.190.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Lim, Yu Jin, Kyubo Kim, Eui Kyu Chie, Wonshik Han, Dong Young Noh, and Sung W. Ha. "Treatment outcome of ductal carcinomain situpatients treated with postoperative radiation therapy." Radiation Oncology Journal 32, no. 1 (2014): 1. http://dx.doi.org/10.3857/roj.2014.32.1.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

El-Ghaffar, Dina, Mohammed Akl, Amal Halim, and Mahfouz Eita. "Outcome and Predictive Factors of Radiation Therapy for Medulloblastoma: Mansoura Experience." Journal of Cancer and Tumor International 5, no. 3 (January 10, 2017): 1–11. http://dx.doi.org/10.9734/jcti/2017/33525.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!